Related Experiment Video

Updated: Feb 7, 2026

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.7K

JAK Inhibitors for Treatment of Alopecia Areata

Eddy H C Wang1, Brigitte N Sallee1, Christina I Tejeda2

  • 1Department of Dermatology, Columbia University, New York, New York, USA.

The Journal of Investigative Dermatology
|July 31, 2018
PubMed

Insights

Targeted therapies for alopecia areata (AA) are emerging. Janus kinase (JAK) inhibitors, repurposed FDA-approved drugs, show promise in reversing hair loss for moderate to severe AA patients.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Alopecia areata (AA) pathogenesis mechanisms are increasingly understood through genetic and preclinical research.
  • Targeted small molecule therapies are under development for AA treatment.
  • Repurposing existing drugs offers a potential therapeutic avenue.

Purpose of the Study:

  • To review current preclinical and clinical studies on Janus kinase (JAK) inhibitors for alopecia areata.
  • To discuss the efficacy and safety of JAK inhibitors in treating AA.
  • To explore the future prospects of JAK inhibitors in AA management.

Main Methods:

  • Literature review of preclinical studies on JAK inhibitors in AA models.
  • Analysis of clinical trial data for JAK inhibitors in patients with moderate to severe AA.
  • Synthesis of findings regarding JAK inhibitor mechanisms and therapeutic outcomes.

Main Results:

  • JAK inhibitors have demonstrated effectiveness in reversing hair loss in patients with moderate to severe AA.
  • Preclinical studies support the role of JAK signaling pathways in AA pathogenesis.
  • Clinical data indicate a positive response to JAK inhibitor therapy in a significant proportion of patients.

Conclusions:

  • JAK inhibitors represent a promising targeted therapy for alopecia areata.
  • Repurposing FDA-approved JAK inhibitors offers a viable treatment strategy for AA.
  • Further research and clinical trials are warranted to optimize JAK inhibitor use in AA.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.2K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
615
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
12.6K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
550
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
685
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K